Historical Valuation
Cabaletta Bio Inc (CABA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.89. The fair price of Cabaletta Bio Inc (CABA) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.14
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Cabaletta Bio Inc (CABA) has a current Price-to-Book (P/B) ratio of 1.53. Compared to its 3-year average P/B ratio of 2.26 , the current P/B ratio is approximately -32.37% higher. Relative to its 5-year average P/B ratio of 1.97, the current P/B ratio is about -22.59% higher. Cabaletta Bio Inc (CABA) has a Forward Free Cash Flow (FCF) yield of approximately -56.53%. Compared to its 3-year average FCF yield of -38.69%, the current FCF yield is approximately 46.12% lower. Relative to its 5-year average FCF yield of -44.69% , the current FCF yield is about 26.49% lower.
P/B
Median3y
2.26
Median5y
1.97
FCF Yield
Median3y
-38.69
Median5y
-44.69
Competitors Valuation Multiple
AI Analysis for CABA
The average P/S ratio for CABA competitors is 17.97, providing a benchmark for relative valuation. Cabaletta Bio Inc Corp (CABA.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CABA
1Y
3Y
5Y
Market capitalization of CABA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CABA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CABA currently overvalued or undervalued?
Cabaletta Bio Inc (CABA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.89. The fair price of Cabaletta Bio Inc (CABA) is between to according to relative valuation methord.
What is Cabaletta Bio Inc (CABA) fair value?
CABA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cabaletta Bio Inc (CABA) is between to according to relative valuation methord.
How does CABA's valuation metrics compare to the industry average?
The average P/S ratio for CABA's competitors is 17.97, providing a benchmark for relative valuation. Cabaletta Bio Inc Corp (CABA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Cabaletta Bio Inc (CABA) as of Jan 09 2026?
As of Jan 09 2026, Cabaletta Bio Inc (CABA) has a P/B ratio of 1.53. This indicates that the market values CABA at 1.53 times its book value.
What is the current FCF Yield for Cabaletta Bio Inc (CABA) as of Jan 09 2026?
As of Jan 09 2026, Cabaletta Bio Inc (CABA) has a FCF Yield of -56.53%. This means that for every dollar of Cabaletta Bio Inc’s market capitalization, the company generates -56.53 cents in free cash flow.
What is the current Forward P/E ratio for Cabaletta Bio Inc (CABA) as of Jan 09 2026?
As of Jan 09 2026, Cabaletta Bio Inc (CABA) has a Forward P/E ratio of -1.29. This means the market is willing to pay $-1.29 for every dollar of Cabaletta Bio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cabaletta Bio Inc (CABA) as of Jan 09 2026?
As of Jan 09 2026, Cabaletta Bio Inc (CABA) has a Forward P/S ratio of 0.00. This means the market is valuing CABA at $0.00 for every dollar of expected revenue over the next 12 months.